Louis Breton, Rampart Bioscience CEO

Ram­part Bio­science rais­es $125M for non-vi­ral gene ther­a­pies

A new Cal­i­for­nia biotech start­up has launched with plans to de­vel­op ge­net­ic med­i­cines that are durable, re­doseable, and per­haps most im­por­tant­ly, don’t over­whelm health bud­gets …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.